• In March 2026, the University of Missouri announced a consulting agreement with Burns & McDonnell for its NextGen MURR research reactor, with BWX Technologies joining as a sub-contractor to support design, licensing and project oversight for this state-of-the-art nuclear medicine and research facility.
• This role further embeds BWX Technologies in the nuclear medical isotope supply chain, aligning its nuclear engineering capabilities with long-term cancer treatment and research demand backed by federal and state funding.
• We’ll now examine how BWX Technologies’ involvement in NextGen MURR could influence its investment narrative, particularly around nuclear medicine growth.

AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

BWX Technologies Investment Narrative Recap

To own BWX Technologies, you need to believe in its role as a specialized nuclear contractor across defense and nuclear medicine, supported by a large, multi‑year backlog. The NextGen MURR subcontract deepens its presence in medical isotopes, but the contract size looks too small to change near term financial drivers or ease the key risk around exposure to U.S. government defense budgets and contract renewals in propulsion and advanced nuclear programs.

The most relevant recent development alongside NextGen MURR is TD Securities’ March 2026 initiation, highlighting BWXT’s “strong nuclear heritage” and technology‑agnostic service model. That view leans on a 50% backlog increase and high‑value awards across government and commercial segments, which ties closely to the core catalyst of growing demand for nuclear solutions in both defense and medicine, with projects like NextGen MURR reinforcing that opportunity set rather than redefining it.

Yet against this promising backdrop, investors should still be aware of how concentrated BWXT’s revenue is in U.S. defense spending and what happens if...

BWX Technologies' narrative projects $3.9 billion revenue and $494.7 million earnings by 2028. This requires 11.1% yearly revenue growth and about a $200 million earnings increase from $294.4 million today.

Uncover how BWX Technologies' forecasts yield a $224.44 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming BWXT could reach about US$5.4 billion in revenue and roughly US$563 million in earnings by 2029, so if you believe medical isotope projects and commercial contracts can offset risks like tighter U.S. defense budgets, your view may sit closer to that bullish camp than the more cautious consensus.

Explore 12 other fair value estimates on BWX Technologies - why the stock might be worth as much as 25% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your BWX Technologies research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BWX Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BWX Technologies' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 56 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.